In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation (vol 123, pg 85, 2017)

被引：1
|
作者：
Sager, Jennifer E. [1 ]
Tripathy, Sasmita [1 ]
Price, Lauren S. L. [1 ]
Nath, Abhinav [2 ]
Chang, Justine [3 ]
Stephenson-Famy, Alyssa [3 ]
Isoherranen, Nina [1 ]
机构：
[1] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA
[2] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA
来源：
BIOCHEMICAL PHARMACOLOGY | 2021年 / 183卷
关键词：
D O I：
10.1016/j.bcp.2020.114306
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] The impact of CYP2D6 mediated drug-drug interaction in elderly: Co-prescription of metoprolol and paroxetine/ fluoxetine
    Bahar, Muh Akbar
    Wang, Yuanyuan
    Bos, Jens H. J.
    Wilffert, Bob
    Hak, Eelko
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 291 - 291
  • [42] Significantly lower CYP2D6 metabolism measured as the O/N-desmethylvenlafaxine metabolic ratio in carriers of CYP2D6*41 versus CYP2D6*9 or CYP2D6*10: a study on therapeutic drug monitoring data from 1003 genotyped Scandinavian patients
    Haslemo, Tore
    Eliasson, Erik
    Jukic, Marin M.
    Ingelman-Sundberg, Magnus
    Molden, Espen
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (01) : 194 - 201
  • [43] CYP2D6 phenotype-genotype discordance and potential new drug-drug interactions.
    Leeder, JS
    Gotschall, RR
    Gaedigk, A
    Kearns, GL
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 216 - 216
  • [44] Pharmacokinetics of diltiazem and its metabolites in relation to CYP2D6 genotype
    Molden, E
    Johansen, PW
    Boe, GH
    Bergan, S
    Christensen, H
    Rugstad, HE
    Rootwelt, H
    Reubsaet, L
    Lehne, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 72 (03) : 333 - 342
  • [45] CYP2D6 Genotyping and Inhibition as Predictors of Adverse Drug Reactions in Depressive Disorders
    Holck, Amanda
    Asp, Marie
    Green, Henrik
    Westrin, Asa
    Reis, Margareta
    JOURNAL OF CLINICAL PSYCHIATRY, 2024, 85 (01)
  • [46] Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction
    Shin, Jaekyu
    Hills, Nancy K.
    Finley, Patrick R.
    PHARMACOTHERAPY, 2020, 40 (06): : 507 - 516
  • [47] Clinical Decision Support to Implement CYP2D6 Drug-Gene Interaction
    Caraballo, Pedro J.
    Parkulo, Mark
    Blair, David
    Elliott, Michelle
    Schultz, Cloann
    Sutton, Joseph
    Rao, Padma
    Bruflat, Jamie
    Bleimeyer, Robert
    Crooks, John
    Gabrielson, Donald
    Nicholson, Wayne
    Vitek, Carolyn Rohrer
    Wix, Kelly
    Bielinski, Suzette J.
    Pathak, Jyotishman
    Kullo, Iftikhar
    MEDINFO 2015: EHEALTH-ENABLED HEALTH, 2015, 216 : 946 - 946
  • [48] Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response
    Goetz, M. P.
    Kamal, A.
    Ames, M. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2008, 83 (01) : 160 - 166
  • [49] Potent inhibition of CYP1A2 and CYP2D6 by the novel antipsychotic drug asenapine in human liver
    Wojcikowski, J.
    Basinska-Ziobron, A.
    Daniel, W. A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S525 - S526
  • [50] Functional phenotyping of the CYP2D6 probe drug codeine in the horse
    S. R. Gretler
    C. J. Finno
    P. H. Kass
    H. K. Knych
    BMC Veterinary Research, 17
12345